Translational research in drug development: challenges and opportunities for pharmacists

Abstract

Translational Research (TR) constitutes a multidirectional, iterative paradigm designed to facilitate the seamless transition of fundamental biomolecular discoveries into robust clinical interventions. The review critically examines the five - tier (T0 - T4) t ranslational trajectory, identifying the systemic biological and operational bottlenecks - most notably the “Valley of Death” and xenogeneic discordance - that perpetuate the high rates of therapeutic attrition within the pharmaceutical pipeline. Furthermore , it delineates the emergence of the pharmacist as a translational catalyst, uniquely equipped to bridge the gap between abstract molecular hypotheses and patient - centric outcomes through the application of pharmacometrics, Physiologically Based Pharmacoki netic (PBPK) modelling, and Model - Informed Drug Development (MIDD). By integrating multi - modal “omics” data with real - world evidence (RWE), the modern pharmacist optimizes the therapeutic index and ensures the clinical scalability of novel chemical entitie s. This paper posits that a paradigm shift toward Open Science frameworks, systems pharmacology, and precision individualization is imperative for overcoming the epistemological opacity of modern drug discovery and achieving global therapeutic equity.